[1]Mario Acunzo, Giulia Romano, Dorothee Wernicke,et al. MicroRNA and cancer--a brief overview. Adv Biol Regul. 2015; 57:1-9.
[2] Han SM, Na HY, Ham O, et al. TCF4-Targeting miR-124 is Differentially Expressed amongst Dendritic Cell Subsets. Immune Netw, 2016; 16(1):61-74.
[3]Hahn M, Burckert JP, Luttenberger CA, et al. Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling. Leukemia, 2018; 32(1):72-82.
[4]Ascierto PA, Simeone E, Sznol M, et al. Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies. Semin Oncol, 2010; 37(5):508-516.
[5] Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84(1):13-22.
[6] DaphnéBenteyn, Carlo Heirman, Aude Bonehill, et al. mRNA-based dendritic cell vaccines. Expert Rev Vaccines. 2015; 14(2):161-176.
[7] Guido Frumento, Tiziana Piazza, Emma Di Carlo, et al. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocrine Metabolic & Immune Disorders-Drug Targets. 2006; 6(3):233-237.
[8] George Malietzis, Gui H Lee, John T Jenkins, et al. Prognostic Value of the Tumor-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review. Cell Communication and Adhesion. 2015; 22(1):9-14.
[9] Yu Q, Lei Y, Huang Y, et al. CYLD expression in dendritic cells involved in theimmunoregulation of pulmonary adenocarcinoma via NF-kappaB pathway. Artificial cells, nanomedicine, and biotechnology 2020; 48(1): 137-142.
[10]Ovidiu Balacescu, Ramona G Dumitrescu, Catalin Marian. MicroRNAs Role in Prostate Cancer. Methods Mol Biol. 2018; 1856:103-117.
[11] Xia H, Cheung WK,Ng SS,et al. Loss of brain-enriched miR-124 enhances the stemlike traits and invasiveness of glioma cells. J. Biol. Chem, 2012; 287:9962–9971.
[12] Zheng H, Song F, Zhang L, et al. Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. Int J Oncol, 2011; 38:1153–1161.
[13] Huang TC, Chang HY, Chen CY, et al. Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett, 2011; 585:3582–3586.
[14] Jiguang Zhang, Yangming Chen, Kai Chen, et al. IL-33 drives the antitumor effects of dendritic cells via upregulating CYLD expression in pulmonary adenocarcinoma. Artif Cells NanomedBiotechnol. 2019; 47(1):1335-1341.
[15]Chao Yang, Qing Jiang. Vitamin E δ-tocotrienol inhibits TNF-α-stimulated NF-κB activation by up-regulation of anti-inflammatory A20 via modulation of sphingolipid including elevation of intracellular dihydroceramides. J NutrBiochem. 2019; 64:101-109.
[16]Songwen Ju, Songguang Ju, Yan Ge, et al. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol. 2009; 21(10):1135-1144.
[17] Lin X, Chen Q, Huang C, et al. CYLD Promotes TNF-alpha-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells. Mediators Inflamm, 2016; 2016: 1542786.
[18] Liu Z,Hazan-Halevy I,Harris DM,et al.STAT-3 activates NF-kappa B in chronic lymphocytic leukemia cells.Mol Cancer Res, 2011; 9( 4) : 507-515.
[19]Herishanu Y,Perez-Galan P,Liu D,et al. The lymph node microenvironment promotes B-cell receptor signaling,NF-kappaB activation,and tumor proliferation in chronic lymphocytic leukemia.Blood,2011; 117( 2) : 563-574
[20] D S Vinay, B S Kwon. Role of 4-1BB in immune responses. Semin Immunol. 1998; 10(6):481-489.
[21] Jun-ying Wu, Feng Qian, He-zuo Lu, et al. The role of costimulatory molecule 4-1BB and CD28 in activating of various T cell subsets from human peripheral blood. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2004; 20(5):533-536.
[22] Hua Zhang, Kristen M Snyder, Megan M Suhoski, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007; 179(7):4910-4918.
[23]Mojtaba Habib-Agahi, MansoorehJaberipour, Peter F Searle. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cell Immunol. 2009; 256(1-2):39-46.
[24]Dinh-Toi Chu, Nguyen Duy Bac, Khanh-Hoang Nguyen, et al. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int J Mol Sci. 2019; 20(8):1822.
[25]Rabah B Zo, Ziwen Long. MiR-124-3p suppresses bladder cancer by targeting DNA methyltransferase 3B. J Cell Physiol. 2018; 234(1):464-474.